Connor, Clark & Lunn Investment Management (CC&L)’s Aegerion Pharmaceuticals AEGR Stock Holding History

Connor, Clark & Lunn Investment Management (CC&L)’s Portfolio AEGR Stock Details AEGR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q4	–	Sell	-106,500	Closed	-$316K	–	1072
2016 Q3	$316K	Hold	106,500	–	–	﹤0.01%	666
2016 Q2	$159K	Buy	106,500 +33,900	+47%	+$77.5K	﹤0.01%	767
2016 Q1	$269K	Sell	72,600 -4,900	-6%	-$30.3K	﹤0.01%	670
2015 Q4	$783K	Buy	77,500 +6,600	+9%	+$79.4K	0.01%	477
2015 Q3	$964K	Buy	+70,900	New	+$1.26M	0.01%	411
2014 Q1	–	Sell	-10,150	Closed	-$765K	–	830
2013 Q4	$765K	Sell	10,150 -2,500	-20%	-$191K	0.01%	423
2013 Q3	$1.11M	Sell	12,650 -1,900	-13%	-$161K	0.01%	254
2013 Q2	$972K	Buy	+14,550	New	+$772K	0.01%	267

Connor, Clark & Lunn Investment Management (CC&L)'s AEGR Position: Q4 2016 in Review

Connor, Clark & Lunn Investment Management (CC&L) sold out of Aegerion Pharmaceuticals (AEGR) in Q4 2016, closing a stake of 106,500 shares — an estimated $316K sold.

Connor, Clark & Lunn Investment Management (CC&L) first reported a position in AEGR in Q2 2013 and held it in 8 quarters. The position peaked at $1.11M in Q3 2013. 0 funds tracked by Wall St. Rank hold AEGR as of Q4 2016.

Connor, Clark & Lunn Investment Management (CC&L) reported no remaining Aegerion Pharmaceuticals position as of Q4 2016 after selling out during the quarter.
Connor, Clark & Lunn Investment Management (CC&L) sold 106,500 Aegerion Pharmaceuticals shares in Q4 2016, an estimated $316K.
Connor, Clark & Lunn Investment Management (CC&L) first reported a position in Aegerion Pharmaceuticals in Q2 2013 and held it in 8 quarters.
Connor, Clark & Lunn Investment Management (CC&L)'s Aegerion Pharmaceuticals position peaked at $1.11M in Q3 2013.
0 funds tracked by Wall St. Rank held Aegerion Pharmaceuticals as of Q4 2016.

Based on Connor, Clark & Lunn Investment Management (CC&L)'s 13F filing for Q4 2016, filed 13 Feb 2017.